Membrane associated matrix metalloproteinases in metastasis

BioEssays

Volumn 21, Issue 11, 1999, Pages 940-949

  Ellerbroek, Shawn M ^a   Stack, M Sharon ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; METALLOPROTEINASE;

BASEMENT MEMBRANE; CELL MEMBRANE; CHEMISTRY; CONNECTIVE TISSUE; ENZYME ACTIVATION; ENZYMOLOGY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; METASTASIS; REVIEW;

BASEMENT MEMBRANE; CELL MEMBRANE; CONNECTIVE TISSUE; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; METALLOENDOPEPTIDASES; NEOPLASM METASTASIS;

EID: 0033230113     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.0.CO;2-J     Document Type: Review

References (88)

1. Ruddon RW. Biology of tumor metastasis. In: Cancer biology, 3rd ed. New York: Oxford University Press, 1995. p 402-427.
2. Cockett MI, Murphy G, Birch BL, O'Connell JP, Crabbe T, Millican AT, Hart IR, Docherty AJ. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp 1998;63:295-313.
3. P. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14:351.
4. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
5. Nagase, H. Cell surface activation of progelatinase A (pro-MMP-2) and cell migration. Cell Res 1998;8:179-186.
6. Sato H, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem (Tokyo) 1996;119:209-215.
7. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
8. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, Decarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
9. Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a cysteine active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci USA 1990;87:364-368.
10. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995;375:244-247.
11. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994;370:61-65.
12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation, and biological functions. Eur J Cell Biol 1997;74:111-122.
13. Corcoran ML, Hewitt RE, Kleiner DE Jr, Sletler-Stevenson WG. MMP-2: expression, activation, and inhibition. Enzyme Protein 1996;49:7-19.
14. Liu YE, Wang M, Greerte J, Su J, Ulrich S, Li H, Sheng S, Alexander P, Sang QA, Shi YE. Preparation and characterization of recombinant tissue inhibitor of metalloproteinase (TIMP-4). J Biol Chem 1997;272:20479-20483.
15. Alvarez OA, Carmichael DR DeCleck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant tissue inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1990;82:589-595.
16. Schulze RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of matrix metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988;48:5539-5545.
17. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, Denhart DT. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989;243:947-950.
18. Valente P, Fassina G, Melchiori A, Masiello L, Chilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson W G, Albini A. TIMP-2 over-expressing reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246-253.
19. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of matrix metalloproteinases. Cancer Res 1992;52:701-708.
20. Gudez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal centrer B cells. Blood 1998;92:1342-1349.
21. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinsase-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-2315.
22. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998;101:1478-1487.
23. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the "hemopexin" domain? Matrix Biol 1997;15:511-518.
24. Itoh Y, Binner S, Nagase H. Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. Biochem J 1995;308:645-651.
25. Liotta LA, Tryggvason K, Pourmotabbed T, Mainardi CL, Hasty KA. Metastatic potential correlates with the enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
26. Yamamoto M, Mohanam S, Sawaya R, Fuller G, Seiki M, Sato H, Gokaslan ZL, Liotta LA, Nicolson GL, Rao JS. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996;56:384-392.
27. Gilles C, Polette M, Piette J, Munaut C, Thompson EW, Birembaut P, Foidart JM. High level of MT-MMP expression is associated with invasiveness of cervical cancer cells. Int J Can 1996;65:209-213.
28. Bando E, Yonemura Y, Endou Y, Sasaki T, Taniguchi K, Fujita H, Fushida S, Fujumura T, Nishimura G, Miwa K, Seiki M. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep 1998;5:1483-1488.
29. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MF. Increased incidence of matrix metalloproteinase in urine of cancer patients. Cancer Res 1998;58:1395-1399.
30. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzyn HJ, Ringert RH. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998;160:1914-1918.
31. Watson SA, Tierney G. Matrix metalloproteinase inhibitors - a review. Biodrugs 1998;9:325-335.
32. Paulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcraft JM, Rogers L, Stamp GW. Stromal expression of 72 kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 1992;141:389-396.
33. Polette M, Nawrocki B, Gilles C, Sato H, Seiki M, Tourneir JM, Birembaut P. MT-MMP Expression and localization in human lung and breast cancers. Virchows Arch 1996;428:29-35.
34. Derugina EI, Bourdon MA, Reisfeld RA, Strongin A. Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 1998;58:3743-3750.
35. Llorens A, Vinyals A, Lopez-Barcons L, Gonzalez-Garrigues M, Fabra A. Metastatic ability of MXT mouse mammary subpopulations correlates with clonal expression and/or membrane-association of gelatinase A. Mol Carcinog 1997;19:54-66.
36. Yu AE, Hewitt RE, Kleiner DE, Stetler-Stevenson WG. Molecular regulation of cellular invasion-role of gelatinase A and TIMP-2. Biochem Cell Biol 1996;74:823-831.
37. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-1051.
38. Young TN, Pizzo SV, Stack MS. A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2. J Biol Chem 1995;270:999-1002.
39. Will H, Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane domain. Eur J Biochem 1995;231:602-608.
40. Takino T, Sata H, Shinagawa A, Seiki M. Identification of the second membrane-type matrix metalloprotease (MT-MMP-2) gene from a human placenta cDNA library. J Biol Chem 1995;270:23013-23020.
41. D'Ortho MP, Will H, Atkinson S, Butler G, Messent A, Gavrilovic J, Smith B, Timpl R, Zardi L, Murphy G. Membrane-type matrix metalloproteinase 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997;250:751-757.
42. Zucker S, Moll UM, Lysik RM, DiMassimo EI, Stetler-Stevenson WG, Liotta LA, Scwedes JW. Extraction of type-IV collagenase/gelatinase from plasma membranes of human cancer cells. Int J Cancer 1990;45:1137-1142.
43. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta 1991;1079: 242-246.
44. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72kDa type IV collagenase. J Biol Chem 1995;270:5331-5338.
45. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, d'Ortho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progeiatinase A. A kinetic study. J Biol Chem 1998;273:871-880.
46. Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty A, Cao J. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1 matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216-1222.
47. Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete JJ, Lichte A, Tschesche H, Maskos K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of matrix metalloproteinse-2, the soluble progelatinase A receptor. EMBO J 1998;17:5238-5248.
48. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP4) to the COOH-terminal hemopexin-like domain of human gelatinase A - TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem 1997;272:15496-15500.
49. Kinoshita T Sato H, Okadam A, Ohuchi E, Imai K, Okada Y, Seiki MJ. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998;273:16098-16103.
50. Atkinson SJ, Crabbe T, Cowell S, Ward RV, Butler MJ, Sato H, Seiki M, Reynolds JJ, Murphy G. Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membrane. J Biol Chem 1995;270:30479-30485.
51. Itoh Y, Ito A, Iwata K, Tanzawa K, Mori Y, Nagase H. Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem 1998;273:24360-24367.
52. Knauper V, Will H, Lopez-OtinC, Smith B, Atkinson SJ, Stanton H, Hembry RM, Murphy G. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-17131.
53. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αVβ3. Cell 1996;85:683-693.
54. Steffensen B, Bigg HF, Overall CM. The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation. J Biol Chem 1998;272:20622-20628.
55. Lehti K, Lohi J, Valtanen H, Keski-Oja J. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem J 1998;334:345-353.
56. Maquoi E, Noel A, Frankenne F, Angliker H, Murphy G, Foidart JM. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor. FEBS Lett 1998;424:262-266.
57. Cao J, Rehemtulla A, Bahou W, Zucker S. Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain. J Biol Chem 1996;271:30174-30180.
58. Cao J, Drews M, Lee HM, Conner C, Bahou WF, Zucker S. The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and the activation of pro-gelatinase A, J Biol Chem 1998;273:34745-34752.
59. Liu G, Thomas L, Warren RA, Enns CA, Cunningham CC, Hartwig JH, Thomas G. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. J Cell Biol 1998;139:1719-1733.
60. Klimpel KR, Molloy SS, Thomas G, Leppla SH. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA 1992;89:10277-10281.
61. Lohi J, Lehti K, Westermarck J, Kahari V, Keski-Oja J. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 1996;239:239-247.
62. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, Zardi L, Murphy G. The activation of proMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J Cell Sci 1998;111:2789-2798.
63. Nakahara H, Howard L, Thompson E W, Sato H, Seiki M, Yeh Y, Chen W T. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 1997;94:7959-7964.
64. Azzam HS, Thompson EW. Collagen-induced activation of the M, 72.000 type IV collagenase in normal and malignant fibroblastoid cells. Cancer Res 1992;52:4540-4544.
65. Seltzer JL, Lee AY, Akers KT, Sudbeck B, Southon EA, Wayner EA, Eisen AZ. Activation of 72-kDa type IV collagenase/gelatinase by normal fibroblasts in collagen lattices is mediated by integrin receptors but is not related to lattice contraction. Exp Cell Res 1994;213:365-374.
66. Gilles C, Polette M, Seiki M, Birembaut P, Thompson E W. Implication of collagen type I-induced membrane-type-1 matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997;76:651-660.
67. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattice induces coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998;273:3604-3610.
68. Teti A, Farina AR, Villanova I, Tiberio A, Taconelli A, Sciortino G, Chambers AF, Gulino A, Mackay AR. Activation of MMP-2 by human GCT23 giant tumor cells induced by osteopontin, bone sialoprotein and GRGDSP peptides is RGD and cell shape change dependent. Int J Cancer 1998;77:82-93.
69. Miyamato S, Akiyama SK, Yamada KM. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function. Science 1995;267:883-885.
70. Seftor REB, Seftor EA, Stetler-Stevenson WG, Hendrix MJC. The 72Kda type IV collagenase is modulated via differential expression of αVβ3 and α5β1 integrins during human melanoma cell invasion. Cancer Res 1993;53:3411-3415.
71. Larjava H, Lyons JG, Salo T, Mekela M, Koivisto L, Birkedal-Hansen H, Akiyama SK, Yamada KM, Heino J. Anti-integrin antibodies induce type IV collagenase expression in keratinocytes. J Cell Physiol 1993;157:190-200.
72. Ellerbroek SM, Fishman DF, Kearns AS, Bafetti LM, Stack MS. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase through β1 integrin. Cancer Res 1999;59:1635-1641.
73. Gilles C, Bassuk JA, Pulyaeva H, Helene Sage E, Foidart JM, Thompson EW. SPARC/Osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 1998;58:5529-5536.
74. Tomesek JJ, Halliday NL, Updike DL, Ahern-Moore JS, Vu TK, Liu RW, Howard EW. Gelatinase A activation is regulated by the organization of the polymerized actin cytoskeleton. J Biol Chem 1997;272:7482-7787.
75. Tyagi SC, Lewis K, Pikes D, Marcello A, Mujumdar VS, Smiley LM, Moore CK. Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol 1998;176: 374-382.
76. Kadono Y, Okada Y, Namiki M, Seiki M, Sato H. Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane type-1 matrix metalloproteinase and invasiveness. Cancer Res 1998;58:2240-2244.
77. Ito A, Yamada M Sato, T Sanekata, K Sato, H Seiki, M Nagase, H Mori, Y. Calmodulin antagonists increase the expression of membrane-type-1 matrix metalloproteinase in human uterine cervical fibroblasts. Eur J Biol 1998;251:353-358.
78. Matsumoto S, Katoh M, Saito S, Watanabe T, Masuho Y. Identification of soluble type of membrane-type matrix metalloproteinase-3 formed by alternatively spliced mRNA. Biochim Biophys Acta 1997;1354:159-170.
79. Puente XS, Pendas AM, Llano E, Velasco G, Lopez-Otin C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res 1996;56:944-949.
80. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, Cardiff RD. CD44(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998;176:206-215.
81. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
82. Partridge CA, Phillips PG, Niedbala MJ, Jeffrey JJ. Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts. Am J Physiol 1997;16:L813-L822.
83. Dolo V, Ginestra A, Cassara D, Violini S, Lucania G, Torrisi MR, Nagase H, Canevari S, Pavan A, Vittorelli ML. Selective localization of matrix metalloproteinase 9, β1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 1998;58:4468-4474.
84. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, Fridman R. High affinity binding of latent matrix metalloproteinase-9 to the α2(IV) chain of collagen IV. J Biol Chem 1998;273:10672-10681.
85. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, Ikawa Y, Ratzkin BJ, Arakawa T, Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci USA 1998;95:13221-13226.
86. Lijnen HR, Silence J, Lemmens G, Frederix L, Collen D. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost 1998;79:1171-1176.
87. Morris VL, MacDonald IC, Koop S, Schmidt EE, Chambers AF, Groom AC. Early interactions of cancer cells with the microvasculature in mouse liver and muscle during hematogenous metastasis: videomicroscopic analysis. Clin Exp Metastasis 1993;11:377-390.
88. Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC. Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 1995;55: 2520-2523.